



## **Canagliflozin (hemihydrate)**

**Catalog No: tcsc3205** 

**Observed Molecular Weight:** 

453.52

Available Sizes
Size: 10mg
Size: 50mg
Size: 100mg
Size: 500mg
Specifications
<b>CAS No:</b> 928672-86-0
<b>Formula:</b> C <sub>24</sub> H <sub>26</sub> FO <sub>5</sub> · <sub>5</sub> S
Pathway: Membrane Transporter/Ion Channel
<b>Target:</b> SGLT
Purity / Grade: >98%
<b>Solubility:</b> DMSO : ≥ 100 mg/mL (220.50 mM)
Alternative Names: JNJ28431754 hemihydrate;TA-7284 hemihydrate





## **Product Description**

Canagliflozin 0.5 H2O(JNJ 28431754; TA 7284) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM, exhibits 413-fold selectivity over hSGLT1.

IC50 value: 2.2 nM

Target: SGLT2

Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes. Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!